Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2024
Companies covered: 15
Tables & Figures: 182
Countries covered: 19
Pages: 130
Download Free PDF

Liver Disease Therapeutics Market
Get a free sample of this reportGet a free sample of this report Liver Disease Therapeutics Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Liver Disease Therapeutics Market Size
The global liver disease therapeutics market size was valued at USD 24.5 billion in 2024. The market is anticipated to grow from USD 25.9 billion in 2025 to USD 50.4 billion in 2034, growing at a CAGR of 7.7% from 2025 to 2034. The market is experiencing significant growth primarily due to the increasing global prevalence of liver diseases across different age demographics.
For example, as per the National Institute of Health (NIH), liver disease accounts for 2 million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide). Excessive alcohol consumption, viral hepatitis (like hepatitis A, B, and C), non-alcoholic fatty liver disease (NAFLD), and certain genetic conditions are some of the common reasons for the high incidence of liver diseases.
Another key driver is the aging population worldwide. With increased life expectancy, age-related conditions, including liver disorders, are increasingly prevalent. The elderly are predisposed to chronic liver disease because of long-term exposure to risk factors such as alcohol, drugs, and metabolic syndrome. This population trend adds to a wider market for liver disease drugs, as global healthcare systems adapt to cater to the needs of the elderly population.
Also, the market growth is supported by the improvement in diagnostic technologies such as PCR testing and cancer diagnostics, which have enhanced the early diagnosis of several liver diseases and consequently increased the market demand. The development of novel liver drugs further supports the market growth. For instance, a breakthrough in liver disease treatment came with the FDA approval of Rezdiffra (resmetirom) in March 2024, marking the first drug specifically for non-alcoholic steatohepatitis (NASH) with liver scarring (fibrosis), but not cirrhosis. This new medication targets protein in the liver to reduce fat, inflammation, and fibrosis, and is intended to be used alongside diet and exercise. Such development and approval of new therapeutics will drive market growth.
Liver disease therapeutics refers to the range of medical treatments and interventions used to manage, treat, or cure diseases and disorders affecting the liver. These therapeutics include pharmaceutical drugs, biologics, and emerging therapies like gene or cell-based treatments. The goal of these medications is to reduce liver damage, manage symptoms, halt disease progression, and, in some cases, restore liver function.
Liver Disease Therapeutics Market Trends
Liver Disease Therapeutics Market Analysis
Based on the product, the global market is segmented into antiviral drugs, vaccines, chemotherapy, targeted therapy, immunosuppressants, immunoglobulins, corticosteroids, and other products. The antiviral drugs segment accounted for the highest market share and was valued at USD 9.7 billion in 2024.
Based on disease type, the global liver disease therapeutics market is categorized into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and other disease types. The hepatitis segment dominated the market with 47.4% market share in 2024.
Based on the gender, the global liver disease therapeutics market is divided into male and female. The male segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 7.2%.
Based on the route of administration, the global liver disease therapeutics market is divided into oral and parenteral. The oral segment dominated the market in 2024 and is anticipated to reach USD 34.7 billion by end of 2034.
Based on the end use, the global liver disease therapeutics market is categorized into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2024 and is expected to reach USD 31.2 billion by 2034.
The North America liver disease therapeutics market dominated the global market with a market share of 38.2% in 2024.
The U.S. market was valued at USD 7.5 billion and USD 7.8 billion in 2021 and 2022, respectively. The market size reached USD 8.5 billion in 2024, growing from USD 8.1 billion in 2023.
Europe liver disease therapeutics market accounted for USD 7.1 billion in 2024 and is anticipated to show considerable growth over the forecast period.
Germany liver disease therapeutics market is anticipated to witness considerable growth over the analysis period.
The Asia Pacific liver disease therapeutics market is expected to witness significant growth over the analysis timeframe.
China liver disease therapeutics market is predicted to grow significantly over the forecast period.
Brazil is experiencing significant growth in the Latin America liver disease therapeutics market.
South Africa liver disease therapeutics market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
Liver Disease Therapeutics Market Share
The global market is characterized by the presence of several players including large multinational corporations, local and regional manufacturers, and start-ups. Top 4 players such as Gilead Sciences, AbbVie, F. Hoffmann-La-Roche, and Bristol-Myers Squibb hold approximately 45% - 50% of the global market.
These key market players are using strategic growth initiatives such as partnerships and acquisitions, new product launches, and geographic expansion to enhance their market presence and gain competitive edge. These players focus on new innovations and develop innovative products centered on customer needs to increase their share in the rapidly growing industry.
Liver Disease Therapeutics Market Companies
Few of the prominent players operating in the liver disease therapeutics industry include:
Liver Disease Therapeutics Industry News
The liver disease therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:
Click here to Buy Section of this Report
Market, By Product
Market, By Disease Type
Market, By Gender
Market, By Route of Administration
Market, By End Use
The above information is provided for the following regions and countries: